Lupus in the modern era (1948-present) The sentinel event which heralded the modern era was the discovery of the LE cell by Hargraves and colleagues in 1948. The investigators observed these cells in ...

Stromal cell therapy is a promising frontier in lupus research, especially for people whose lupus doesn’t respond to other treatments (called refractory lupus). We were the first lupus organization in ...

The transcription factor interferon regulatory factor 5 (IRF5) has previously been implicated in systemic lupus erythematosus (SLE) development, but its precise role in this process is unknown.

Leukocytoclastic vasculitis (LCV), where neutrophils are predominant, and lymphocytic vasculitis, where lymphocytes are predominant, are inflammatory cells ... syndromes in LE (Lupus Foundation ...

When researchers reintroduced AHR-activating molecules into the blood samples taken from those with lupus, the immune cells balanced out again. "We found that if we either activate the AHR pathway ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Long-lived plasma cells, which produce autoantibodies in diseases such as systemic lupus erythematosus (SLE), are an as yet unexplored therapeutic target in such antibody-mediated disorders.

The FDA has awarded Fast Track Designation (FTD) Adicet Bio, Inc’s novel allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy ADI-001 for adults with refractory systemic lupus ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.